-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CnEaP6+jEb11EzdqR95ym/WXn5oGsifzTHrIseTfkdZCsX2DcZRV1ghAcqtDDJoa NuGX1lr6jnthA7xL71nzCg== 0000950123-11-015804.txt : 20110222 0000950123-11-015804.hdr.sgml : 20110221 20110218173438 ACCESSION NUMBER: 0000950123-11-015804 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20101118 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20110222 DATE AS OF CHANGE: 20110218 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Fibrocell Science, Inc. CENTRAL INDEX KEY: 0000357097 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870458888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-31564 FILM NUMBER: 11625627 BUSINESS ADDRESS: STREET 1: 405 EAGLEVIEW BOULEVARD CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 484-713-6000 MAIL ADDRESS: STREET 1: 405 EAGLEVIEW BOULEVARD CITY: EXTON STATE: PA ZIP: 19341 FORMER COMPANY: FORMER CONFORMED NAME: ISOLAGEN INC DATE OF NAME CHANGE: 20020320 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN FINANCIAL HOLDING INC /DE DATE OF NAME CHANGE: 19960330 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN FINANCIAL HOLDING INC /CO DATE OF NAME CHANGE: 19921008 8-K/A 1 w81643ae8vkza.htm FORM 8-K/A e8vkza
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
Amendment No. 1
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
DECEMBER 15, 2010
Date of Report (date of Earliest Event Reported)
FIBROCELL SCIENCE, INC.
(Exact Name of Registrant as Specified in its Charter)
         
DELAWARE   001-31564   87-0458888
(State or Other Jurisdiction of
Incorporation or Organization) 		  (Commission File No.)   (I.R.S. Employer Identification No.)
405 EAGLEVIEW BLVD., EXTON, PA 19341
(Address of principal executive offices and zip code)
(484) 713-6000
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).
 
 

 

 

Explanatory Note
This Amendment No. 1 (this “Amendment”) amends the Current Report on Form 8-K filed by Fibrocell Science, Inc. (“Fibrocell”) with the Securities and Exchange Commission on January 18, 2011, which disclosed that Fibrocell had completed a private placement of securities. This Amendment is filed solely to correct the exhibit references included in Item 9.01 of the Current Report on Form 8-K. The complete and accurate list of exhibits appears below in Item 9.01 of this Amendment. This Amendment does not reflect any events that have occurred after the Form 8-K was originally filed on January 18, 2011.
Item 9.01.   Financial Statements and Exhibits
(d) Exhibits
         
Exhibit No.   Exhibit
  3.1    
Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock, dated December 8, 2010 (incorporated by reference to Exhibit 3.2 of the Form 8-K filed December 27, 2010).
  4.1    
Form of Common Stock Purchase Warrant used for the Transactions (incorporated by reference to Exhibit 4.1 of the Form 8-K filed February 15, 2011).

2

 

SIGNATURE
     Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  FIBROCELL SCIENCE, INC.
 		  
Date: February 18, 2011  By:   /s/ Declan Daly    
    Declan Daly,   
    Chief Operating Officer   
 

3

-----END PRIVACY-ENHANCED MESSAGE-----